

TX CLINICAL CRITERIA & PROCEDURE

CRITERIA NAME: Reslizumab (Cinqair®)	CRITERIA ID: TX.CC.PHAR.16
BUSINESS UNIT: Superior HealthPlan	FUNCTIONAL AREA: Pharmacy
EFFECTIVE DATE: 10/18/2021	PRODUCT(S): STAR, STAR PLUS, STAR HEALTH, STAR KIDS, CHIP, CHIP Perinate
REVIEWED/REVISED DATE: 11/30/2021, 08/10/2022, 11/14/2022, 08/1/2023, 03/15/2024, 05/01/2024, 03/20/2025	REGULATOR MOST RECENT APPROVAL DATE(S): N/A

CRITERIA STATEMENT:

The purpose of this clinical criteria is to provide a guide to medical necessity reviews for reslizumab (Cinqair®).

PURPOSE:

Consistent with the regulation at 42 CFR Section 438.210 and 42 CFR Section 457.1230(d), services covered under managed care contracts, including clinician-administered drugs, must be furnished in an amount, duration, and scope that is no less than the amount, duration, and scope for the same services specified in the state plan. While MCOs may place appropriate limits on drugs, MCOs may not use a standard for determining medical necessity that is more restrictive than what is used in the state plan, i.e., developed by the Vendor Drug Program. For example, if a member is denied a clinician administered drug in managed care because of the MCO's prior authorization criteria but would have received the drug under the criteria specified in the state plan, then the MCO's prior authorization criteria would violate the amount, duration, and scope requirements cited above. HHSC intends to amend the Managed Care Contracts at the next opportunity to include this requirement. This same standard applies to CHIP formulary and CAD coverage.

Refer to the Outpatient Drug Services Handbook of the Texas Medicaid Provider Procedure Manual for more details on the clinical criteria and prior authorization requirements.

SCOPE:

This criteria applies to all directors, officers, and employees of Centene Corporation, its affiliates, health plans, and subsidiary companies (collectively, the "Company").

DEFINITIONS:

SHP = Superior HealthPlan

CPS = Centene Pharmacy Services

POLICY:

It is the policy of Superior HealthPlan (SHP) and Centene Pharmacy Services (CPS) to follow state guidance for medical necessity review of reslizumab (Cinqair®); procedure code: J2786.

Description/Mechanism of Action:

Reslizumab (Cinqair®) is a humanized interleukin-5 antagonist monoclonal antibody (IgG4 kappa).

FDA Approved Indications:

Reslizumab (Cinqair®) is indicated for add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype.

PROCEDURE:

Provider must submit documentation (which may include office chart notes and lab results) supporting that member has met all approval criteria.

I. Initial Approval Criteria

A. Severe Asthma (must meet all):

1. The client has a diagnosis of severe asthma with eosinophilic phenotype (as defined by the National Heart, Lung and Blood Institute's Guidelines for the Diagnosis and management of Asthma) (diagnosis codes J44.50, J44.51 J45.52, and J82.83).
2. The client is 18 years of age or older.
Note: Exceptions may be considered for clients younger than the FDA approved age on a case-by-case basis by the Medical Director.
3. Documentation showing symptoms are inadequately controlled with use of a minimum of 3 months of controller medication (which includes but is not limited to a long-acting beta2-agonist [LABA], an inhaled or oral corticosteroid, leukotriene receptor antagonist [LTRA], or theophylline, unless the individual is intolerant of, or has a medical contraindication to these agents.
Note: Exceptions to the criteria above will be considered on a case-by-case basis, which will require a letter from the prescribing provider stating the medical necessity for Cinqair, the client's asthma severity level, and the duration of current and past therapies and lack of asthma control. Consideration for these exceptions will be reviewed by the Medical Director.
4. Cinqair is not prescribed concurrently with Xolair or any other interleukin-5 antagonist.
5. Any client with a preexisting helminth infection should be treated prior to receiving Cinqair therapy. If there is an active helminth infection, the client should be treated with anti-helminth treatment. If there is no response, treatment with Cinqair should be discontinued until parasitic infection resolves.

Approval duration: 6 months

II. Continued Therapy

A. Severe Asthma (must meet all):

1. The client has a satisfactory clinical response to therapy (documentation of clinical improvement must include one or more of the following (a, b, or c):
 - a. Decreased utilization of rescue medications;
 - b. Increase in predicted FEV1 (forced expiratory volume) from pretreatment baseline;
 - c. Reduction in reported asthma-related symptoms, as evidenced by decreases in frequency or magnitude of one or more of the following symptoms:
 - Asthma attacks
 - Chest tightness or heaviness
 - Coughing or clearing throat
 - Difficulty taking deep breath or difficulty breathing out
 - Shortness of breath
 - Sleep disturbance, night waking, or symptoms upon awakening

- Tiredness
 - Wheezing/heavy breathing/fighting for air
2. Documentation stating client has not exhibited symptoms of hypersensitivity or anaphylaxis (bronchospasm, hypotension, syncope, urticaria, and/or angioedema) after administration of Cinqair
 3. Cinqair is not prescribed concurrently with Xolair or any other interleukin-5 antagonist.
 4. The client must be compliant with their Cinqair regimen in order to qualify for additional prior authorizations. The provider must submit a statement documenting compliance with the requests for each renewal.
 5. Any client with a preexisting helminth infection should be treated prior to receiving Cinqair therapy. If there is an active helminth infection, the client should be treated with anti-helminth treatment. If there is no response, treatment with Cinqair should be discontinued until parasitic infection resolves.

Note: Requests for clients who do not meet the above criteria will be reviewed for medical necessity by the Medical Director. After lapses in treatment of 3 months or greater, prior authorization requests submitted with documentation will be reviewed by a Medical Director.

REFERENCES:

Texas Medicaid Provider Procedures Manual: Outpatient Drug Services Handbook

ATTACHMENTS:

REVISION LOG

REVISION TYPE	REVISION SUMMARY	DATE APPROVED & PUBLISHED
Ad Hoc	Added diagnosis codes	11/30/2021
Ad Hoc	Formatted to new template Added compliance statement requirement for continued approval for asthma Added that treatment must not be used with any other IL-5 antagonist	08/10/2022
Ad Hoc	Extended Approval Duration for continuation of therapy to 12 months	11/14/2022
Ad Hoc	Updated drug name to: reslizumab (Cinqair) in Policy section Added additional PA requirement for all indications for initial and continuation criteria: <ul style="list-style-type: none"> • a client with a preexisting helminth infection should be treated prior to receiving mepolizumab therapy • If there is an active helminth infection, the client should be treated with anti-helminth treatment. If there is no response, treatment should be discontinued until parasitic infection resolves Updated criteria step 3 for initial therapy for indication of moderate to severe asthma to: <ul style="list-style-type: none"> • Documentation showing symptoms are inadequately controlled with use of a minimum of 3 months of controller 	08/01/2023

	<p>medication (which includes but is not limited to a long-acting beta2-agonist [LABA], an inhaled or oral corticosteroid, leukotriene receptor antagonist [LTRA], or theophylline, unless the individual is intolerant of, or has a medical contraindication to these agents.</p> <p>Update criteria verbiage to “the client” for consistency throughout document</p> <p>Updated age requirements throughout by removing \geq symbol.</p> <p>Removed criteria points under asthma indication referencing: smoking, pulmonary function tests and eosinophil counts.</p> <p>Updated Scope section to include Centene Pharmacy Services</p> <p>Updated Functional Area to reflect Pharmacy only</p> <p>Updated Products section to include CHIP Perinate</p> <p>Updated Definitions section</p>	
Ad Hoc Review	<p>Updated to TX.CC.PHAR format template</p> <p>Added Centene copyright statement</p>	03/15/2024
Ad Hoc Review	Added J82.83 under I.A.1 as clarification for eosinophilic asthma	05/01/2024
Annual Review	<p>Updated revision dates to align with format of XX/XX/XXXX throughout document</p> <p>Removed reference to Fasenra and Nucala in I.A.4 and II.A.3. to align with verbiage in TMHP CAD Manual (reslizumab may not be used concurrently with omalizumab or any other interleukin-5 antagonist).</p> <p>Added punctuation in I.A.2.a.and b.</p>	03/20/2025

©2024 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.